Collaboration to advance multiplexed biomarker panel for early Type 1 diabetes diagnosis

Genalyte (San Diego, CA) has launched a Type 1 diabetes multiplexed antigen panel that runs on the company's silicon photonics-driven Maverick detection system, and is the first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in Type 1 diabetes. The company is also collaborating with the Barbara Davis Center for Childhood Diabetes (BDC) at the University of Colorado School of Medicine (Aurora, CO) to further develop and test multiplexed antigen panels for the early detection of Type 1 diabetes.

Related: Multiplexed detection system from Genalyte garners CE mark approval
 
The T1D antigen panel was developed as part of the first phase of a Small Business Innovation Research (SBIR) grant awarded to the company to develop multiplexed assays for the early detection and monitoring of Type 1 diabetes.  The $500,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases also provides support for expansion of the approach to allow autoantibody response profiling by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.
 
George Eisenbarth, MD, PhD, and Liping Yu, MD, at BDC established assays for measuring islet autoantibodies, explains Martin Gleeson, PhD, chief scientific officer at Genalyte. Islet autoantobodies eventually destroy the pancreatic islet cells that produce insulin; to that end, the Maverick detection platform can detect and track the process from an early stage, when interventions to interrupt the disease process may be feasible, he says.
 
Available to diabetes researchers worldwide, the T1D antigen panel requires only a 2 to 5 μL serum or plasma sample and provides results in less than 15 minutes without the use of dyes, fluorescent probes, or radioactive labels. The panel measures autoantibodies to insulin, proinsulin, GAD 65, GAD 67, IA-2 (PTPRN, ICA512), phogrin (PTPRN2, IA-2ß), and ZnT8 (SLC30A8).

For more information, visit http://genalyte.com/maverick-type-1-diabetes-t1d-assay-kit/.         

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

LuxCath optical tissue characterization catheter enables real-time monitoring during cardiac ablation

A study used optical tissue characterization technology for the first time in procedures to treat arrhythmia patients.

EUV spectral imaging tool can map cell composition in 3D

A newly developed spectral imaging instrument enables observation of how cells respond to new medications at a minute level.

Fluorescence Imaging: Optical filtering basics for life sciences

Optical filters can have a dramatic effect on outcomes in life sciences. These principles demonstrate how next-generation thin film enhances excitation and emission in fluorescence bioimaging syste...

Photoacoustics/Biomedical Imaging: Photoacoustic imaging progresses toward medical diagnostics

Recent technological developments in laser and transducer hardware, contrast agents, and image reconstruction algorithms have helped to advance photoacoustic (or optoacoustic) imaging.  

Translational Research: Bench-to-bedside: Progress, pioneers, and 21st Century Cures

The NIH/SPIE Biophotonics from Bench to Bedside workshop (Sept. 24-25) featured speakers and posters presenting exciting translational research in technologies and applications.

Legislation promises biophotonics opportunities

The 21st Century Cures Act (H.R. 6) was a focal point at the NIH/SPIE Biophotonics from Bench to Bedside workshop.

Zeiss partners with Molecular Imaging Platform at McGill University Health Centre

Zeiss has entered into a partnership with the Research Institute of the McGill University Health Centre's Molecular Imaging Platform.

Biophotonics innovator Ozcan wins International Commission for Optics Prize

UCLA professor and biophotonics innovator Aydogan Ozcan has received the International Commission for Optics (ICO) Prize.

New biosensor provides spatially resolved hydrogen peroxide sensing in cells

A new biosensor is able to show the location of the key cellular signaling chemical inside living cells with high resolution over time.

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2015. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS